Please enable JS

Manufacturing

Our strategy is to become a fully integrated biopharmaceutical company in China.

In addition to assembling an experienced internal research and development team, we have already built a cGMP-compliant small molecule facility capable of supporting clinical and commercial production and have begun construction of a cGMP-compliant large molecule facility capable of supporting clinical production of our drug candidates in China.

The construction of our 1,000L large molecule pilot facility was completed in June 2018.